MDL Isentris Selected by Novo Nordisk to Integrate R&D Informatics and

    Business Editors/Biotech Writers/High-Tech Editors
    BIOWIRE2K

    SAN LEANDRO, Calif.--(BUSINESS WIRE)--Jan. 10, 2005--Elsevier MDL is pleased to announce that Novo Nordisk has selected the MDL(R) Isentris(R) information management and integration platform for its R&D operations. Isentris is the first fully supported, open-standards-based, n-tier discovery informatics platform specifically designed for life sciences researchers. Designed to operate over a Wide Area Network, Isentris is unique in integrating business processes, data and applications across R&D. Novo Nordisk is already using the DiscoveryGate(R) product, which is built on Isentris and provides one-query access to the world's largest integrated environment of chemical, pharmacological and patent databases.
    "Isentris is our most ambitious product to date and accelerates R&D by providing a free flow of internal and external information, rapid deployment of new workflows and flexible project views," said Lars Barfod, president and chief executive officer of Elsevier MDL. "We are delighted that Novo Nordisk has elected to build their new, modern R&D information architecture on our flagship enterprise software."
    Novo Nordisk has licensed the entire MDL(R) Isentris(R) Enterprise Edition platform, which includes the revolutionary MDL(R) Base user interface, MDL(R) Draw chemical drawing and rendering software, MDL(R) Core Interface middle tier with Integrating Data Source and the MDL(R) Direct chemical data cartridges for molecules and reactions. Full compatibility with MDL ISIS ensures easy migration to Isentris.
    To learn more about how MDL Isentris integrates and energizes life sciences discovery, contact your Elsevier MDL Account Manager, or request information using the "Contact Us" form available at www.mdl.com.

    About Elsevier MDL

    Elsevier MDL provides informatics, database, workflow and decision support solutions that accelerate the discovery and development of successful new drugs by improving the speed and quality of scientists' decision making. Commercial, academic and government life sciences researchers around the world depend on Elsevier MDL for innovative and reliable discovery informatics software solutions and services augmented by 400 Elsevier chemistry and life sciences journals and related products. For more information, visit www.mdl.com.
    Elsevier is a world-leading publisher of scientific, technical and medical information products and services. Working in partnership with the global science and health communities, the company publishes more than 1,800 journals and 2,200 new books per year, in addition to offering a suite of innovative electronic products, online reference works and subject-specific portals. For more information, visit www.elsevier.com.
    Elsevier is part of Reed Elsevier Group plc, a world-leading publisher and information provider. Reed Elsevier's ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange). For more information, visit www.reedelsevier.com.

    MDL, Isentris and DiscoveryGate are registered trademarks in the United States, and "Powering the Process of Invention" is a trademark of MDL Information Systems, Inc. in the United States and other countries. All rights reserved.

--30--ALX/sf*

CONTACT: Elsevier MDL Dr. Phil McHale, 510-357-2222 ext. 3541 email: p.mchale@mdl.com

KEYWORD: CALIFORNIA NETHERLANDS UNITED KINGDOM INTERNATIONAL EUROPE Biomedical INDUSTRY KEYWORD: CHEMICALS/PLASTICS MEDICAL PHARMACEUTICAL BIOTECHNOLOGY SOFTWARE MARKETING AGREEMENTS SOURCE: Elsevier MDL

Copyright Business Wire 2005